US 11,980,623 B2
Solid dosage formulations of an orexin receptor antagonist
Paul A. Harmon, Norristown, PA (US); Narayan Variankaval, Plainsboro, NJ (US); Michael Lowinger, Ridgewood, NJ (US); Chad David Brown, Pittstown, NJ (US); and Francis Flanagan, Conshohocken, PA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed on Sep. 14, 2021, as Appl. No. 17/474,322.
Application 17/474,322 is a continuation of application No. 16/059,439, filed on Aug. 9, 2018, granted, now 11,160,811.
Application 16/059,439 is a continuation of application No. 14/404,147, granted, now 10,098,892, issued on Oct. 16, 2018, previously published as PCT/US2013/042959, filed on Nov. 26, 2014.
Claims priority of provisional application 61/787,686, filed on Mar. 15, 2013.
Claims priority of provisional application 61/653,539, filed on May 31, 2012.
Prior Publication US 2022/0062295 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/551 (2006.01); A61K 9/20 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/551 (2013.01) [A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01)] 9 Claims
 
1. A pharmaceutical composition comprising:
suvorexant in an amorphous form; and
a polymer selected from the group consisting of a polyvinylpyrrolidinone-polyvinyl acetate copolymer, a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, and hydroxypropyl methyl cellulose acetate succinate;
wherein the pharmaceutical composition comprises 5 mg, 10 mg, 15 mg or 20 mg of suvorexant, and wherein the suvorexant is present in a form that contains at least 90 weight % of the amorphous form of suvorexant relative to other morphological forms of suvorexant.